Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Today on Living Oklahoma we were joined by Rebecca Jones.She spoke to Matt Stafford about here journey with Alzheimer's and ...

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...